Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC-3: Imiquimod for High-grade CIN
NCT02917746Unknown
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2016
- Primary completion
- Jul 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Treatment efficacy of imiquimod and LLETZ treatment at 20 weeks and Identification of predictive biomarkers for treatment efficacy. Status: unknown.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02917746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917746.